Pharma & Biotech

In a strategic pivot aimed at capturing a broader patient base, Novo Nordisk is aggressively promoting a new oral version...

The independent public trading story for CureVac has reached its conclusion. BioNTech's successful takeover has led to a suspension of...

Pfizer Inc. used the prominent J.P. Morgan Healthcare Conference to detail its future roadmap, but the market's response has been...

After a prolonged period of significant share price declines, Sangamo Therapeutics is back in the spotlight following a critical regulatory...

The remarkable ascent of Eli Lilly's stock has hit a potential stumbling block. Following months of impressive gains, the equity...

Tilray Brands has released its second-quarter financial results, showcasing significant operational improvements that have resonated with investors. The company's latest...

Bayer's shares enter a pivotal week with the commencement of the J.P. Morgan Healthcare Conference in San Francisco. Investors are...

The era of CureVac as a publicly traded company has concluded. BioNTech SE has finalized its acquisition of the mRNA...

In a bold move to capture broader market share, Novo Nordisk has initiated a significant strategic pivot in the lucrative...

Eli Lilly and Company has opened 2026 with a clear strategic push to diversify and strengthen its business. A significant...